Study: Abbott’s CardioMEMS reduces HF hospital admissions, improves quality of life
Abbott (NYSE:ABT) presented data at ACC 2017 from a study of its CardioMEMS HF system, touting that results showed it can reduce heart failure hospital admissions and improve quality of life in patients with heart failure.
Results from the study, which included more than 1,100 Medicare patients, indicated a 46% reduction in heart failure hospitalizations at 6 months after receiving the CardioMEMS system, and a 34% reduction at 12 months.
Data also indicated an average reduction of more than $10,500 in comprehensive health care costs at 6-months post-implant in CardioMEMS patients compared to 6-months prior. At 12-months, the analysis reported a $13,190 reduction in cost per patient.
“These results support the clinical effectiveness and potential cost savings of using an implantable hemodynamic monitor to help with heart failure management. Reducing heart failure hospitalizations is an important goal for patients and hospitals alike, and may help to improve long-term clinical outcomes and quality of life for our patients,” Dr. Akshay Desai of the Brigham and Women’s Hospital said in a prepared statement.
“The reduction in hospitalizations and costs associated with heart failure confirmed by these data shows that proactive patient management with the CardioMEMS HF System is successful in mainstream practice and results in improved clinical outcomes. Success with this technology for us means helping patients get back to living their life,” Abbott HF biz med director Dr. Philip Adamson said in a press release.